Changes in plasma interleukin-8 and tumor necrosis factor-α levels during the early treatment period as a predictor of the response to sorafenib in patients with unresectable hepatocellular carcinoma
| Autor: | Yoshiki Murakami, Hiroyasu Morikawa, Akihiro Tamori, Masaru Enomoto, Yuga Teranishi, Ayako Iida-Ueno, Le Thi Thanh Thuy, Atsushi Hagihara, Norifumi Kawada, Sawako Uchida-Kobayashi, Hideki Fujii |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Male
Sorafenib Cancer Research medicine.medical_specialty Carcinoma Hepatocellular Antineoplastic Agents Toxicology Gastroenterology Cohort Studies 03 medical and health sciences 0302 clinical medicine Stable Disease Predictive Value of Tests Internal medicine medicine Humans Pharmacology (medical) Interleukin 8 Aged Retrospective Studies Pharmacology Dose-Response Relationship Drug Tumor Necrosis Factor-alpha business.industry Interleukin-8 Liver Neoplasms medicine.disease Survival Analysis Oncology Response Evaluation Criteria in Solid Tumors 030220 oncology & carcinogenesis Hepatocellular carcinoma Cohort Female 030211 gastroenterology & hepatology Tumor necrosis factor alpha business Biomarkers Progressive disease medicine.drug |
| Zdroj: | Cancer Chemotherapy and Pharmacology. 82:857-864 |
| ISSN: | 1432-0843 0344-5704 |
| DOI: | 10.1007/s00280-018-3681-x |
| Popis: | This study aimed to identify a biomarker for predicting the response to sorafenib in patients with hepatocellular carcinoma (HCC). Of 100 patients with unresectable HCC who received sorafenib treatment in our institute (Cohort A), 48 had stored plasma samples collected within 28 days before the start of treatment (Cohort B). Concentrations of 18 plasma cytokines were measured in plasma samples using a sandwich immunoassay with multiplexed fluorescent bead-based technology. Among 27 patients with follow-up plasma samples taken at 5–10 days of treatment (Cohort C), changes in the 18 cytokines were also evaluated. In Cohort A, progressive disease (PD) according to the modified Response Evaluation Criteria in Solid Tumors (mRECIST) was associated with poor overall survival by multivariate analysis (p = 0.024). In Cohort B, no significant differences in baseline concentrations of α-fetoprotein, des-γ-carboxy prothrombin, or the 18 cytokines were found between patients with PD and those with stable disease (SD) or partial response (PR). In Cohort C, the increase in interleukin-8 and tumor necrosis factor-α (TNF-α) was significant in the PD group (p = 0.0063 and p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink